Onset Delayed News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Teplizumab delayed progression to clinical type 1 diabetes by about 2 years compared with placebo in individuals destined to develop the condition because of autoantibody levels.

United statesEmilyk simsAshleigh palmerJohn sharrettsProvention bioDivision of diabetesIndiana university school of medicineDrug administrationDepartment of pediatricsAmerican diabetes associationLipid disordersDrug evaluationOnset delayedNew england journalScience translational medicineIndiana university school